BRAF mutation (any)

Any BRAF mutation (V600 and non-V600 classes) detected by sequencing; used as a predictive and, in some settings, prognostic marker.

CI-BIO-00000019BRAF graph →NCIt C40430 Tumor-agnostic · 4 approval rows

Also calledBRAF-mutant · BRAF-mutated · non-V600 BRAF · class II/III BRAF

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (32)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Melanoma	75	72	2	1	3 / 40 / 14 / 18 / 0
Malignant Colorectal Neoplasm	67	54	13	—	1 / 43 / 10 / 12 / 1
Cutaneous Melanoma	22	22	—	—

Derived

Drugs with predictive evidence (43)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	92	72	20	A	55 / 22	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +16
TrametinibSmall Molecule	53	51	2	A	50 / 2	Childhood Low Grade Glioma, Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma +13
DabrafenibSmall Molecule	40	33	7	A	34 / 11	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Ganglioglioma +9
CetuximabMonoclonal Antibody	24	11	13	A	9 / 10	Malignant Colorectal Neoplasm, Solid Neoplasm
PanitumumabMonoclonal Antibody	14	8	6	B	5 / 4	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	12	5	7	B	5 / 6	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	10	9	1	C	9 / 1	Childhood Pilocytic Astrocytoma, Cutaneous Melanoma, Malignant Colorectal Neoplasm, Melanoma +1
CobimetinibSmall Molecule	7	7	—	A	8 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	6	6	—	A	6 / 0	Malignant Colorectal Neoplasm, Melanoma
Mitogen-Activated Protein Kinase Kinase Inhibitor	6	6	—	B	5 / 0	Cutaneous Melanoma, Melanoma
BevacizumabMonoclonal Antibody	5	3	2	B	3 / 2	Malignant Colorectal Neoplasm, Spindle Cell Sarcoma
BRAF Inhibitor	5	5	—	B	4 / 0	Melanoma
SelumetinibSmall Molecule	5	4	1	B	2 / 2	Childhood Pilocytic Astrocytoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
OxaliplatinSmall Molecule	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm, Melanoma
TovorafenibSmall Molecule	2	2	—	A	4 / 0	Childhood Low Grade Glioma
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
TemsirolimusSmall Molecule	2	2	—	C	2 / 0	Spindle Cell Sarcoma
U0126	2	—	2	D	0 / 2	Cutaneous Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
Regorafenib AnhydrousSmall Molecule	2	1	1	C	0 / 1	Gastrointestinal Stromal Tumor
MEK Inhibitor RO4987655	2	—	2	B	—	Melanoma
AlpelisibSmall Molecule	1	1	—	B	1 / 0	Malignant Colorectal Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	A	1 / 0	Melanoma
BelvarafenibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Chemotherapy	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
Dabrafenib/Trametinib Regimen	1	1	—	C	1 / 0	Histiocytic Sarcoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
EverolimusSmall Molecule	1	1	—	D	1 / 0	Childhood Low Grade Glioma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
MEK Inhibitor REC-4881	1	1	—	C	1 / 0	Cutaneous Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
Pan-RAF Inhibitor LY3009120Small Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
RefametinibSmall Molecule	1	—	1	C	0 / 1	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (214)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 101–150 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E11
Cetuximab + Gefitinib + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1408 5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified E… (full text at CIViC) PMID 22281684 · Prahallad et al., 2012 · Open in CIViC	civic
Panitumumab + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID1413 Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed in 12 patients with metastatic colorectal cancer (CRC) who had progressed on chemotherapy. Two patien… (full text at CIViC) PMID 25589621 · Yaeger et al., 2015 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID1589 Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subse… (full text at CIViC) PMID 27325282 · Pietrantonio et al., 2016 · Open in CIViC	civic
Cobimetinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID1141 Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetini… (full text at CIViC) PMID 23934108 · Hatzivassiliou et al., 2013 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Malignant NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID11672 This NCI-MATCH trial was conducted in 35 patients of which 29 were included in the primary efficacy analysis with tumors with BRAF V600E mutations, and treated with a combination of dabrafenib and tra… (full text at CIViC) PMID 32758030 · Salama et al., 2020 · Open in CIViC	civic
Vemurafenib	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID5959 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 4 pati… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Melanoma	Predictive	B	Supports Sensitivity Response	5	accepted	EID95 Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma. PMID 24583796 · Menzies et al., 2014 · Open in CIViC	civic
〃	Melanoma	Predictive	B	Supports Sensitivity Response	5	accepted	EID6178 Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (… (full text at CIViC) PMID 28891408 · Long et al., 2017 · Open in CIViC	civic
〃	Melanoma	Predictive	B	Supports Sensitivity Response	5	accepted	EID6938 In this Phase III trial (NCT01584648 COMBI-d), previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF V600E (359 patients) or V600K (61 patients) received dabrafenib and t… (full text at CIViC) PMID 25265492 · Long et al., 2014 · Open in CIViC	civic
〃	Melanoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID6940 In this Phase I and II study (NCT01072175) patients with metastatic melanoma were given dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy. From V600E patients, 45 received monot… (full text at CIViC) PMID 23020132 · Flaherty et al., 2012 · Open in CIViC	civic
Dactolisib + SelumetinibCombination	Melanoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID1005 49 BRAF-mutant melanoma cell lines from patients not previously treated with BRAF inhibition were analyzed. 21 exhibited primary resistance to BRAF inhibition using PLX4720. Inhibition of MEK1/2 (AZD6… (full text at CIViC) PMID 26678033 · Penna et al., 2016 · Open in CIViC	civic
BRAF V6005
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID7355 A randomized clinical trial was done with metastatic colorectal cancer (mCRC) patients (50 in the control group, 49 in the experimental group) with BRAF V600 mutations and RAS wild type that were enro… (full text at CIViC) Open in CIViC	civic
Atezolizumab + Cobimetinib + VemurafenibCombination	Melanoma	Predictive	A	Supports Sensitivity Response	4	accepted	EID11238 In this phase 3, randomised, double-blind, placebo-controlled trial, 514 patients with unresectable stage IIIc–IV, BRAFV600 mutation-positive melanoma were randomly assigned to either 28-day cycles of… (full text at CIViC) PMID 32534646 · Gutzmer et al., 2020 · Open in CIViC	civic
Cobimetinib +
BRAF L485_P490del1
Pan-RAF Inhibitor LY3009120	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID1267 Cells harboring in-frame deletions in BRAF in the L485-P490 amino acid region were found to be sensitive to the RAF dimer inhibitor LY3009120, but not sensitive to the BRAF-selective inhibitors vemura… (full text at CIViC) PMID 26732095 · Chen et al., 2016 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Mutation + NRAS MutationHRAS BRAF NF1 KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11681 In this phase II study of the arm E of the NCI-COG pediatric MATCH trial, 20 patients (median age: 14) were treated with Selumetinib. High-grade glioma (n=7) and rhabdomyosarcoma (n=7) were the most c… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Inactivating Mutation + NRAS MutationHRAS NF1 BRAF KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11696 In this Phase II study, 20 patients harboring activating RAS gene mutations (KRAS = 8, NRAS = 3. HRAS = 1), BRAF V600E mutations, and NF1 inactivating mutations (n=7) were treated with Selumetinib. No… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
BRAF Mutation1
Trametinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	4	accepted	EID936 In this screen of 218 solid cancer cell lines, BRAF mutations were predictive of response to the MEK inhibitor GSK1120212. 26 of these cell lines had the BRAF V600E mutation, one cell line had a G469A… (full text at CIViC) PMID 22169769 · Jing et al., 2012 · Open in CIViC	civic
BRAF G464V1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5964 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF G469A1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5965 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF G496A1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5966 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF N581S1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5967 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF G466V1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5968 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF G596R1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5969 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF G606E1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5970 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF L597Q1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5971 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF P731T1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5972 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF intron 9 rearrangement1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5973 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF intron 10 rearrangement1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5974 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively Of 26 patient… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF Fusion1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5975 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively Of 26 patient… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF D594G1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID7556 RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R). PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
BRAF N486_P490del1
Trametinib	Malignant Pancreatic Neoplasm	Predictive	C	Supports Sensitivity Response	3	accepted	EID7730 In a case report, a patient with pancreatic cancer harboring BRAF N486-P490del was treated with trametinib. Within 4 weeks of initiating therapy, her serum CA19-9 had fallen from 36,000 to 8,100 U/mL,… (full text at CIViC) PMID 29903880 · Aguirre et al., 2018 · Open in CIViC	civic
BRAF Fusion1
Vemurafenib	Malignant Pancreatic Neoplasm	Predictive	C	Supports Sensitivity Response	2	accepted	EID5977 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One of 23 pa… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF Fusion1
Belvarafenib	Melanoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID13151 A patient with metastatic melanoma of unknown primary harboring an AGK-BRAF fusion with an intact BRAF kinase domain received belvarafenib 450 mg twice daily after progression on pembrolizumab, dacarb… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
BRAF V600D3
BRAF Inhibitor	Melanoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7616 In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC	civic
BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination	Melanoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7629 In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC	civic
Dabrafenib	Melanoma	Predictive	B
BRAF G4691
BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination	Melanoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID7634 In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC	civic
BRAF V600_K601>E1
BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination	Melanoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7630 In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC	civic
BRAF A598V1
BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination	Melanoma	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID7635 In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC	civic
BRAF V600K5
Dabrafenib	Melanoma	Predictive	B	Supports Sensitivity Response	—	accepted	EID2505 Patients were treated with a specific RAF inhibitor (dabrafenib), which improved overall survival of patients with BRAF mutations (P<0.003), compared to non-treated patients with BRAF mutations. Patie… (full text at CIViC) PMID 21343559 · Long et al., 2011 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Melanoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID6179 Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (… (full text at CIViC) PMID 28891408 · Long et al., 2017 · Open in CIViC	civic
〃	Melanoma	Predictive	B	Supports Sensitivity Response
BRAF V600E + BRAF V600M1
Dabrafenib	Melanoma	Predictive	C	Supports Sensitivity Response	1	accepted	EID73 A single 66-year old male patient with advanced melanoma thought to have concomitant BRAF V600E and V600M mutations responded rapidly to dabrafenib. His shoulder lesion reduced by 60% after 1 week of … (full text at CIViC) PMID 23031422 · Ponti et al., 2012 · Open in CIViC	civic
BRAF V600E + BRAF V600K1
Dabrafenib + TrametinibCombination	Melanoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID93 This was a Phase I and II study (NCT01072175) of dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy in patients with metastatic melanoma. Cutaneous squamous-cell carcinoma was… (full text at CIViC) PMID 23020132 · Flaherty et al., 2012 · Open in CIViC	civic
BRAF Amplification + BRAF V6001
Dabrafenib + TrametinibCombination	Melanoma	Predictive	C	Supports Resistance	4	accepted	EID7677 In a retrospective study, authors analyzed BRAF V600 mutated melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and geneti… (full text at CIViC) PMID 25452114 · Long et al., 2014 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (458)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Dabrafenib	US FDA	Tumor-agnostic	the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated	approved	Mar 16, 2023	openfda
Dabrafenib	US FDA	Tumor-agnostic	the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated	approved

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (629)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 333 recruiting · 118 active phase 3 · 2,987 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 251–300 of 629 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05425940	Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer(STELLAR-303)	active not recruiting	Phase 3	901	ExelixisINDUSTRY	16	Jul 17, 2026	clinicaltrials
NCT01087554	Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer	active not recruiting	Phase 1	249	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT02525757	MPDL3280A With Chemoradiation for Lung Cancer	active not recruiting	Phase 2	52	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	Phase 2	59	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	Phase 1 / Phase 2	37	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT03599752	Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases	active not recruiting	Phase 2	40	M.D. Anderson Cancer CenterOTHER	2	Jul 16, 2026	clinicaltrials
NCT04188145	A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer(BEVAMAINT)	active not recruiting	Phase 3	400	Centre Hospitalier Universitaire DijonOTHER	1	Jul 16, 2026	clinicaltrials
NCT05092373	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	recruiting	Phase 1	43	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT06906341	Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers	recruiting	Phase 2	270	Corcept TherapeuticsINDUSTRY	8	Jul 16, 2026	clinicaltrials
NCT06948448	A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer	recruiting	Phase 2	144	Ono Pharmaceutical Co., Ltd.INDUSTRY	6	Jul 16, 2026	clinicaltrials
NCT05000294	Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types	recruiting	Phase 1 / Phase 2	29	University of FloridaOTHER	1	Jul 13, 2026	clinicaltrials
NCT03148418	A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)	active not recruiting	Phase 3	382	Hoffmann-La RocheINDUSTRY	32	Jul 10, 2026	clinicaltrials
NCT03942328	Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer	recruiting	Phase 1 / Phase 2	85	Mayo ClinicOTHER	1	Jul 10, 2026	clinicaltrials
NCT06109779	Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)	active not recruiting	Phase 3	760	AstraZenecaINDUSTRY	21	Jul 10, 2026	clinicaltrials
NCT07637851	Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer(RegeNovar)	not yet recruiting	Phase 1 / Phase 2	43	ARCAGY/ GINECO GROUPOTHER	1	Jul 10, 2026	clinicaltrials
NCT07689539	Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation	not yet recruiting	Phase 3	360	Jiangxi Kvvit Pharmaceutical Co., Ltd.INDUSTRY	0	Jul 8, 2026	clinicaltrials
NCT03085056	Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer	active not recruiting	Early Phase 1	13	Memorial Sloan Kettering Cancer CenterOTHER	1	Jul 7, 2026	clinicaltrials
NCT03737643	Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients(DUO-O)	active not recruiting	Phase 3	1,407	AstraZenecaINDUSTRY	20	Jul 7, 2026	clinicaltrials
NCT04238624	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	active not recruiting	Phase 2	16	Memorial Sloan Kettering Cancer CenterOTHER	1	Jul 6, 2026	clinicaltrials
NCT07300150	A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors	recruiting	Phase 1	210	PAQ Therapeutics, Inc.INDUSTRY	2	Jul 6, 2026	clinicaltrials
NCT04576117	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma	active not recruiting	Phase 3	300	National Cancer Institute (NCI)NIH	2	Jul 2, 2026	clinicaltrials
NCT04626635	A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers(COMBINE-EGFR-1)	active not recruiting	Phase 1 / Phase 2	548	Regeneron PharmaceuticalsINDUSTRY	7	Jul 2, 2026	clinicaltrials
NCT05047250	A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer	active not recruiting	Phase 3	60	Hoffmann-La RocheINDUSTRY	1	Jul 2, 2026	clinicaltrials
NCT06819007	Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01)	recruiting	Phase 3	582	Daiichi SankyoINDUSTRY	25	Jul 2, 2026	clinicaltrials
NCT06839105	A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies	recruiting	Phase 1	214	Shanghai Junshi Bioscience Co., Ltd.OTHER	1	Jul 2, 2026	clinicaltrials
NCT04227028	Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC	active not recruiting	Phase 1	5	City of Hope Medical CenterOTHER	1	Jul 1, 2026	clinicaltrials
NCT04835805	A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.	active not recruiting	Phase 1	65	Genentech, Inc.INDUSTRY	5	Jul 1, 2026	clinicaltrials
NCT05722886	DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol(DETERMINE)	recruiting	Phase 2 / Phase 3	825	Cancer Research UKOTHER	1	Jul 1, 2026	clinicaltrials
NCT07079631	A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer	recruiting	Phase 1 / Phase 2	482	BioNTech SEINDUSTRY	5	Jul 1, 2026	clinicaltrials
NCT06794086	SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases(SPARKLE-L)	recruiting	Phase 3	24	Jun HuangOTHER	1	Jun 30, 2026	clinicaltrials
NCT06412198	A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations	recruiting	Phase 1 / Phase 2	31	M.D. Anderson Cancer CenterOTHER	1	Jun 26, 2026	clinicaltrials
NCT03175432	Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases	active not recruiting	Phase 2	29	M.D. Anderson Cancer CenterOTHER	1	Jun 25, 2026	clinicaltrials
NCT03872947	A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors	active not recruiting	Phase 1	138	Toray Industries, IncINDUSTRY	2	Jun 23, 2026	clinicaltrials
NCT05005403	Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan	recruiting	Phase 1	694	AbbVieINDUSTRY	6	Jun 23, 2026	clinicaltrials
NCT05584670	A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	542	SanofiINDUSTRY	6	Jun 23, 2026	clinicaltrials
NCT05825625	NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing	active not recruiting	Phase 2	35	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER	1	Jun 23, 2026	clinicaltrials
NCT06813079	Using Tumor Models to Determine Treatments	recruiting	Phase 2	25	University Health Network, TorontoOTHER	1	Jun 23, 2026	clinicaltrials
NCT07662031	Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer	not yet recruiting	Phase 2	25	Washington University School of MedicineOTHER	1	Jun 23, 2026	clinicaltrials
NCT05525858	KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II(KOSMOSII)	recruiting	—	1,000	Seoul National University Bundang HospitalOTHER	1	Jun 22, 2026	clinicaltrials
NCT05843188	Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer	active not recruiting	Phase 2	155	University Health Network, TorontoOTHER	1	Jun 22, 2026	clinicaltrials
NCT04722575	Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma(NEO-TIM)	active not recruiting	Phase 2	95	Fondazione Melanoma OnlusOTHER	1	Jun 18, 2026	clinicaltrials
NCT05694715	Combination Therapy in Cancers With Mutations in DNA Repair Genes	recruiting	Phase 1	24	University of California, San FranciscoOTHER	1	Jun 18, 2026	clinicaltrials
NCT06381154	Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer	active not recruiting	Phase 2	24	Mayo ClinicOTHER	1	Jun 18, 2026	clinicaltrials
NCT07339488	Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma(ILDR-03)	recruiting	Phase 2	43	Chuangzhen ChenOTHER	1	Jun 18, 2026	clinicaltrials
NCT05999812	Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer	active not recruiting	Phase 2	22	University of Texas Southwestern Medical CenterOTHER	1	Jun 17, 2026	clinicaltrials
NCT06106308	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	active not recruiting	Phase 2	110	Cardiff OncologyINDUSTRY	1	Jun 16, 2026	clinicaltrials
NCT06642844	Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment(PHARBEVACOL)	recruiting	Phase 3	244	University Hospital, ToursOTHER	1	Jun 16, 2026	clinicaltrials
NCT02671435	A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors	active not recruiting	Phase 1 / Phase 2	383	MedImmune LLCINDUSTRY	11	Jun 15, 2026	clinicaltrials
NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-03)	active not recruiting	Phase 1 / Phase 2	74	Novartis PharmaceuticalsINDUSTRY	8	Jun 15, 2026	clinicaltrials
NCT00494182	Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	active not recruiting	Phase 2	48	M.D. Anderson Cancer CenterOTHER	1	Jun 12, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Atezolizumab

EU EMA

—

Urothelial carcinoma Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC): after prior platinum containing chemotherapy, or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1). Early-stage non-small cell lung cancer (NSCLC) Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK positive NSCLC (see section 5.1 for selection criteria). Advanced NSCLC  Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy (see section 5.1 for selection criteria).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancer (SCLC)Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1). Triple-negative breast cancer (TNBC)Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1). Urothelial carcinoma (UC) Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic UC: after prior platinum containing chemotherapy, or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1). Early-stage non-small cell lung cancer (NSCLC) Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK positive NSCLC (see section 5.1 for selection criteria). Advanced NSCLC  Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate target…

approved

Sep 20, 2017

ema

Approval rows flagged tumor-agnostic (4)

Associated cancers (32)

Drugs with predictive evidence (43)

Predictive evidence items (214)

Approvals mentioning the linked drugs (458)

Active trials (629)

Linked publications (142)